Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Esperion Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of oral, non-statin therapies for the treatment of cardiovascular disease, particularly for patients with elevated low-density lipoprotein cholesterol (LDL‑C). The company operates within the cardiovascular therapeutics and lipid management segments of the pharmaceutical industry, targeting patients who are statin-intolerant or require additional LDL‑C lowering beyond statins.
Esperion’s primary commercial products are NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in the United States, marketed for LDL‑C reduction, with corresponding products NILEMDO® and NUSTENDI® marketed outside the U.S. through partners. The company was founded in 2008 by Roger S. Newton and went public in 2013, evolving from a development-stage biotechnology firm into a commercial-stage company following U.S. FDA approval of its lead products in 2020. A key strategic milestone was the publication of the CLEAR Outcomes trial, which demonstrated cardiovascular risk reduction and strengthened Esperion’s competitive positioning.
Business Operations
Esperion operates primarily as a single-segment biopharmaceutical company centered on the discovery, development, and commercialization of cholesterol-lowering therapies. Revenue is generated through U.S. product sales of NEXLETOL® and NEXLIZET®, as well as collaboration and royalty revenue from ex-U.S. licensing arrangements. The company does not manufacture products internally and relies on third-party contract manufacturers for production and supply.
Internationally, Esperion markets its products through strategic partners, most notably Daiichi Sankyo Europe GmbH, which holds commercialization rights across major European markets. Esperion retains control over core intellectual property related to bempedoic acid and its fixed-dose combination therapies. No material joint ventures have been disclosed beyond regional licensing and commercialization agreements.
Strategic Position & Investments
Esperion’s strategy is centered on expanding adoption of bempedoic acid-based therapies as a differentiated, oral, once-daily LDL‑C lowering option with a favorable tolerability profile. The company is leveraging outcomes data from the CLEAR Outcomes trial to drive broader guideline inclusion, payer coverage, and physician adoption, particularly among statin-intolerant and high cardiovascular risk populations.
Rather than pursuing broad diversification, Esperion has concentrated investment on lifecycle management of its existing products and maximizing value from international partnerships. The company has not announced material acquisitions in recent periods, and its investment activity has remained focused on post-marketing studies, regulatory expansion, and commercial infrastructure. Data inconclusive based on available public sources regarding near-term expansion into non-cardiovascular therapeutic areas.
Geographic Footprint
Esperion is headquartered in Ann Arbor, Michigan, with primary commercial operations in North America. The United States represents the company’s largest revenue-generating market, supported by a dedicated commercial sales force targeting cardiologists, primary care physicians, and lipid specialists.
Internationally, Esperion maintains a presence across Europe through licensing and commercialization partnerships, with approved products in multiple European Union countries. The company does not report direct operational infrastructure in Asia-Pacific, Latin America, or Africa, but retains the ability to expand its geographic reach through additional regional partnerships.
Leadership & Governance
Esperion is led by an executive team with experience in cardiovascular medicine, pharmaceutical commercialization, and public-company governance. The leadership emphasizes disciplined capital allocation, evidence-based commercialization, and long-term value creation driven by clinical outcomes.
Key executives include:
- Sheldon Koenig – President and Chief Executive Officer
- Dan O’Connor – Executive Vice President and Chief Financial Officer
Esperion was founded by Roger S. Newton, a long-time cardiovascular drug developer. Public disclosures emphasize a leadership philosophy centered on scientific rigor, regulatory credibility, and focused execution within cardiovascular disease. Data inconclusive based on available public sources regarding additional current C‑suite roles beyond those listed above.